Founded in 2023, Dualitas Therapeutics is building a pipeline of bispecific antibodies that simultaneously engage two immune-cell targets to achieve greater efficacy than single-target monoclonal antibodies. Its internally developed DualScreen platform scans the entire cell surface (“surfaceome”) to identify hundreds of thousands of target pairings and select the most promising therapeutic combinations using a proximity-biology approach. The two lead preclinical candidates are DTX-103, aimed first at asthma and other allergic diseases, and DTX-102, initially focused on rheumatoid arthritis; specific targets for both remain undisclosed. One of these programs is expected to be advanced in-house, while the other may be partnered with a larger pharmaceutical company. Management plans to move the internal lead into clinical trials within 18–24 months and will evaluate clinical differentiation versus current standards of care to guide trial design. The company’s scientific leadership includes co-founders Forbes Huang (COO/CBO) and Greg Lazar (CSO), with Rich Murray serving as interim CEO.

Total raised

$65M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2025